Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics results from a German observational study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics results from a German observational study | Kraemer et al. BMC Psychiatry 2011 11 173 http www.biomedcentral.com 1471-244X 11 173 BMC Psychiatry RESEARCH ARTICLE Open Access Prevalence of metabolic syndrome in patients with schizophrenia and metabolic changes after 3 months of treatment with antipsychotics -results from a German observational study 1 1 23 1 Susanne Kraemer Anette Minarzyk Thomas Forst Daniel Kopf and Hans-Peter Hundemer Abstract Background This observational study explored the prevalence of metabolic syndrome MetS in adult in- and outpatients with untreated or treated schizophrenia at baseline and month-3 after initiation or switch of antipsychotic treatment. Methods MetS-prevalence AHA NHLB-definition was assessed and Clopper-Pearson 95 confidence intervals CIs were calculated. Factors associated with MetS were explored through univariate and multivariate logistic regressions both visits . Results MetS-prevalence was 44.3 CI 39.8 48.9 at baseline and 49.6 CI 45.0 54.2 at month-3. Previously unmedicated patients showed the lowest baseline MetS-prevalence 24.7 CI 18.3 32.1 . MetS-prevalence was not significantly different regardless if patients previously received typical or atypical antipsychotics. Increased MetS-risk was associated with somatic comorbidity and non-smoking at both visits and with non-psychiatric co-medication male sex and increased C-reactive protein at month-3. Conclusions At baseline MetS was most prevalent in patients with previous antipsychotic medication. Limited metabolic changes were observed 3 months after switch initiation of antipsychotic therapy. Trial Registration Number ClinicalTrials.gov Identifier n.a. Background Several studies have reported increased mortality in patients with schizophrenia. Besides higher risks for cancer respiratory and cerebrovascular disorders and of death from suicide or homicide the main cause is cardiovascular disease 1-7 . Even before antipsychotic medication became available in the 1950s abnormal responses to insulin and .